Clinical trials: Childhood Neoplasm
Carcinoma, Transitional Cell, Bladder Cancer
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of advanced or metastatic bladder cancer.
- Conditions
- Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
- Trial name
- NCT00722553
- Testing
- Pralatrexate Injection, Vitamin B12, Folic Acid
- Where
- 19 sites in United States, Argentina and 4 more
- Volunteers
- 30 people
- Sponsor
- Acrotech Biopharma Inc.
Advanced Solid Tumor, Metastatic Cancer
FIH XON7 in Advanced/Metastatic Solid Tumors
This is a two-stage trial consisting of a Part I, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), if any, and Recommended Part 2 Dose (RP2D) of XON7, followed by a Part II component to…
- Trial name
- FIPO23 (NCT06154291)
- Testing
- XON7
- Where
- 5 sites in Belgium, France
- Volunteers
- 255 people
- Sponsor
- Xenothera SAS
Chronic Lymphocytic Leukemia
Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis
This project will attempt to validate the utilization of a stable isotope kinetic biomarker (KineMarkerTM) as a predictive test for disease progression in early stage chronic lymphocytic leukemia (CLL).
- Trial name
- CRC011 (NCT00481858)
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- KineMed
Tumors
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced…
- Trial name
- NCT00395434
- Testing
- Combretastatin A4 Phosphate (CA4P), Bevacizumab (Avastin)
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Mateon Therapeutics
Primary Breast Cancer
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
Metastatic bone disease is an important prognostic factor for survival which will in median be close to two years after first diagnosis of osseous metastases.
- Trial name
- MRD-1 (NCT00172068)
- Testing
- Zoledronic acid + Calcium/Vitamin D
- Where
- 4 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer.
- Conditions
- Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma
- Trial name
- SHARON (NCT04150042)
- Testing
- Melphalan, BCNU, Vitamin B12B
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- General Oncology, Inc.
Leukemia
Aminopterin in Treating Patients With Refractory Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory…
- Trial name
- NCT00003305
- Testing
- aminopterin, leucovorin calcium
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- Genzyme, a Sanofi Company
Breast Cancer
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before.
- Trial name
- NCT03734029
- Testing
- Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin
- Where
- 208 sites in United States, Austria and 18 more
- Volunteers
- 557 people
- Sponsor
- Daiichi Sankyo
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Maxillofacial Bone Defects, Alveolar Bone Atrophy
Gene-activated Matrix for Bone Tissue Repair in Maxillofacial Surgery
The purpose of this study is to evaluate safety and efficacy of gene-activated matrix ("Nucleostim") for regeneration of bone tissue in maxillofacial area.
- Conditions
- Maxillofacial Bone Defects, Alveolar Bone Atrophy, Jaw Fractures, Maxillofacial Bone Deformities
- Trial name
- NCT02293031
- Testing
- Gene-activated matrix "Nucleostim"
- Where
- 2 sites in Russia
- Volunteers
- 12 people
- Sponsor
- NextGen Company Limited
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Solid Tumor, Ovarian Cancer
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors
- Conditions
- Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, BRCA 1 /2 and / or HRD
- Trial name
- NCT07156253
- Testing
- SYN818 and Olaparib will be administered
- Where
- 2 sites in China
- Volunteers
- 110 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Chordoma, Unresectable Malignant Neoplasm
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
QUILT 3.091 Chordoma Vaccine: Phase 1B/2 NANT Chordoma Vaccine vs Radiation in Subjects with Unresectable Chordoma.
- Trial name
- NCT03647423
- Testing
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-051
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participants with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
- Trial name
- NCT05639751
- Testing
- PRT3789, Docetaxel
- Where
- 32 sites in United States, France and 3 more
- Volunteers
- 135 people
- Sponsor
- Prelude Therapeutics Incorporated
Metastatic Breast Cancer, Metastatic Solid Cancer
HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
This phase II study aims to confirm the diagnostic performance and accuracy of 68Ga-ABS011 PET/CT in determining the HER2 expression status, and to evaluate 68Ga-ABS011's ability to drive changes in therapeutic treatment.
- Trial name
- HERMIA (NCT06369831)
- Testing
- 68Ga-NOTA-ABSCINT-HER2 PET/CT
- Where
- 7 sites in Austria, Belgium
- Volunteers
- 60 people
- Sponsor
- Abscint NV/SA
Colorectal Cancer
A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.
The purpose of this study is to determine the maximum tolerated dose (which will be the dose recommended for a Phase 2 study), safety, tolerability and pharmacokinetic profile (study of movement of the drug within the body…
- Trial name
- NCT02726334
- Testing
- BNC101 Solution for Infusion, BNC101 in combination with FOLFIRI
- Where
- 4 sites in Australia
- Volunteers
- 22 people
- Sponsor
- Bionomics Limited
Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer.
- Trial name
- NCT00054899
- Testing
- EP2101
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Epimmune
Myelofibrosis, Primary Myelofibrosis
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving…
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Trial name
- NCT04551053
- Testing
- parsaclisib, ruxolitinib
- Where
- 177 sites in United States, Austria and 17 more
- Volunteers
- 177 people
- Sponsor
- Incyte Corporation
Anal Neoplasm
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
This is a phase 2, open-label efficacy study of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) in adult men and women who are human immunodeficiency virus (HIV) negative with histologically…
- Trial name
- NCT03499795
- Testing
- VGX-3100, CELLECTRA™ 5PSP
- Where
- 3 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Inovio Pharmaceuticals
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent
- Trial name
- NCT05645744
- Testing
- Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product.
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mustang Bio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.